α1-antitrypsin deficiency in lung and liver disease

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalHospital Practice
Volume24
Issue number5
StatePublished - 1989

Fingerprint

Lung Diseases
Liver Diseases
Inborn Genetic Diseases
Protease Inhibitors
Chronic Obstructive Pulmonary Disease
Liver
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

α1-antitrypsin deficiency in lung and liver disease. / Buist, A (Sonia).

In: Hospital Practice, Vol. 24, No. 5, 1989, p. 51-59.

Research output: Contribution to journalArticle

@article{99ec16d79ba14faf98d05fde10008d44,
title = "α1-antitrypsin deficiency in lung and liver disease",
abstract = "Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.",
author = "Buist, {A (Sonia)}",
year = "1989",
language = "English (US)",
volume = "24",
pages = "51--59",
journal = "Hospital practice (1995)",
issn = "2154-8331",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - α1-antitrypsin deficiency in lung and liver disease

AU - Buist, A (Sonia)

PY - 1989

Y1 - 1989

N2 - Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

AB - Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

UR - http://www.scopus.com/inward/record.url?scp=0024336214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024336214&partnerID=8YFLogxK

M3 - Article

C2 - 2497126

AN - SCOPUS:0024336214

VL - 24

SP - 51

EP - 59

JO - Hospital practice (1995)

JF - Hospital practice (1995)

SN - 2154-8331

IS - 5

ER -